

## Second-generation CAR-T Cells Targeting CD22

<b>Drug Name</b>	***0102
<b>Description</b>	A novel cancer immunotherapy consists of human peripheral blood mononuclear cells derived T cells transduced with a lentiviral vector encoding a second-generation chimeric antigen receptor targeting CD22. The cell therapy is in early clinical trials for the treatment of acute lymphocytic leukemia.
<b>Target</b>	CD22
<b>Drug Modality</b>	CAR-T Cells
<b>Indication</b>	Acute Lymphocytic Leukemia
<b>Product Category</b>	Cancer Immunotherapy
<b>Mechanism of Action</b>	Targeting B-Cell Receptor CD22
<b>Status</b>	Clinical Trials
<b>Patent</b>	Granted

### More Detail Available Upon Request

We look forward to hearing from you.